Overview of human cytomegalovirus pathogenesis

Methods in Molecular Biology

Volumn 1119, Issue , 2014, Pages 15-28

  Nogalski, Maciej T ^a   Collins McMillen, Donna ^a   Yurochko, Andrew D ^a  

^a NONE

Author keywords

AIDS patients; Congenital infection; Human cytomegalovirus; Immunocompetent; Immunocompromised; Oncogenesis; Transplant patients; Vascular disease; Viral pathogenesis

Indexed keywords

AIDS PATIENT; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; INFLAMMATORY DISEASE; LATENT VIRUS INFECTION; MONONUCLEOSIS; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE; VIRUS PATHOGENESIS; VIRUS REACTIVATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; CYTOMEGALOVIRUS; GENETICS; METHODOLOGY; MOLECULAR BIOLOGY; PATHOGENICITY; PATHOLOGY; TRANSPLANTATION; VIROLOGY; VIRUS ACTIVATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MOLECULAR BIOLOGY; TRANSPLANTATION; VIRUS ACTIVATION;

EID: 84908501711     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-788-4_2     Document Type: Article

References (120)

1. Mocarsk ES Jr, Shenk T, Pass RF (2007) Cytomegaloviruses. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott Williams & Wilkins, Philadelphia, PA, pp 2701-2772.
2. Britt W (2008) Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. In: Stinksi MF, Shenk T (eds) Human cytomegaloviruses. Springer, Berlin, pp 417-470.
3. Bravender T (2010) Epstein-Barr virus, cytomegalovirus, and infectious mononucleosis. Adolesc Med State Art Rev 21: 251-264, ix-64, ix.
4. Eddleston M, Peacock S, Juniper M, Warrell DA (1997) Severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 24: 52-56.
5. Söderberg-Nauclér C (2008) HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 41: 218-223.
6. Michaelis M, Doerr HW, Cinatl J (2009) The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 11: 1-9.
7. Caposio P, Orloff SL, Streblow DN (2011) The role of cytomegalovirus in angiogenesis. Virus Res 157: 204-211.
8. Streblow DN, Dumortier J, Moses AV, Orloff SL, Nelson JA (2008) Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing. Curr Top Microbiol Immunol 325: 397-415.
9. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK (2013) The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev 26: 86-102.
10. Klemola E, Von Essen R, Henle G, Henle W (1970) Infectious-mononucleosis-like disease with negative heterophile agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies. J Infect Dis 121: 608-614.
11. Jordan MC, Rousseau W, Stewart JA, Noble GR, Chin TD (1973) Spontaneous cytomegalovirus mononucleosis. Clinical and laboratory observations in nine cases. Ann Intern Med 79: 153-160.
12. Wreghitt TG, Teare EL, Sule O, Devi R, Rice P (2003) Cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 37: 1603-1606.
13. Streblow DN, Dumortier J, Moses AV, Orloff SL, Nelson JA (2008) Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing. In: Stinksi MF, Shenk T (eds) Human cytomegaloviruses. Springer, Berlin, pp 397-416.
14. Adam E, Melnick JL, Probtsfield JL, Petrie BL, Burek J, Bailey KR, McCollum CH, DeBakey ME (1987) High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 2: 291-293.
15. Hendrix MG, Salimans MM, van-Boven CP, Bruggeman CA (1990) High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 136: 23-28.
16. Melnick JL, Petrie BL, Dreesman GR, Burek J, McCollum CH, DeBakey ME (1983) Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 2: 644-647.
17. Nieto FJ, Adam E, Sorlie P, Farzadegan H, Melnick JL, Comstock GW, Szklo M (1996) Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 94: 922-927.
18. Gyorkey F, Melnick JL, Guinn GA, Gyorkey P, DeBakey ME (1984) Herpesviridae in the endothelial and smooth muscle cells of the proximal aorta in atherosclerotic patients. Exp Mol Pathol 40: 328-339.
19. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE (1996) Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 335: 624-630.
20. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE (1994) Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265: 391-394.
21. Hussain T, Burch M, Fenton MJ, Whitmore PM, Rees P, Elliott M, Aurora P (2007) Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation 115: 1798-1805.
22. Söderberg-Nauclér C, Emery VC (2001) Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 71: SS24-SS30.
23. Zhu J, Quyyumi AA, Norman JE, Csako G, Epstein SE (1999) Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. J Am Coll Cardiol 34: 1738-1743.
24. Chan G, Nogalski MT, Stevenson EV, Yurochko AD (2012) Human cytomegalovirus induction of a unique signalsome during viral entry into monocytes mediates distinct functional changes: a strategy for viral dissemination. J Leukoc Biol 92: 743-752.
25. Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6: 508-519.
26. 3 integrins. Proc Natl Acad Sci USA 105: 5531-5536.
27. Falk E (2006) Pathogenesis of atherosclerosis. J Am Coll Cardiol 47: C7-C12.
28. Lusis AJ (2000) Atherosclerosis. Nature 407: 233-241.
29. Streblow DN, Soderberg-Naucler C, Vieira J, Smith P, Wakabayashi E, Ruchti F, Mattison K, Altschuler Y, Nelson JA (1999) The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 99: 511-520.
30. Streblow DN, Orloff SL, Nelson JA (2001) Do pathogens accelerate atherosclerosis? J Nutr 131: 2798-2804.
31. Chan G, Nogalski MT, Yurochko AD (2012) Human cytomegalovirus stimulates monocyte-to-macrophage differentiation via the temporal regulation of caspase 3. J Virol 92: 10714-10723.
32. Streblow DN, Kreklywich CN, Smith P, Soule JL, Meyer C, Yin M, Beisser P, Vink C, Nelson JA, Orloff SL (2005) Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33. Am J Transplant 5: 436-442.
33. Orloff SL, Hwee YK, Kreklywich C, Andoh TF, Hart E, Smith PA, Messaoudi I, Streblow DN (2011) Cytomegalovirus latency promotes cardiac lymphoid neogenesis and accelerated allograft rejection in CMV naïve recipients. Am J Transplant 11: 45-55.
34. Streblow DN, Kreklywich CN, Andoh T, Moses AV, Dumortier J, Smith PP, Defilippis V, Fruh K, Nelson JA, Orloff SL (2008) The role of angiogenic and wound repair factors during CMV-accelerated transplant vascular sclerosis in rat cardiac transplants. Am J Transplant 8: 277-287.
35. Gombos RB, Brown JC, Teefy J, Gibeault RL, Conn KL, Schang LM, Hemmings DG (2013) Vascular dysfunction in young, midaged and aged mice with latent cytomegalovirus infections. Am J Physiol Heart Circ Physiol 304: H183-H194.
36. Tang-Feldman YJ, Lochhead SR, Lochhead GR, Yu C, George M, Villablanca AC, Pomeroy C (2013) Murine cytomegalovirus (MCMV) infection upregulates P38 MAP kinase in aortas of Apo E KO mice: a molecular mechanism for MCMV-induced acceleration of atherosclerosis. J Cardiovasc Transl Res 6: 54-64.
37. Bhattacharjee B, Renzette N, Kowalik TF (2012) Genetic analysis of cytomegalovirus in malignant gliomas. J Virol 86: 6815-6824.
38. Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, Bland KI, Cobbs CS (2002) Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360: 1557-1563.
39. Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS (2003) High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol 170: 998-1002.
40. Harkins LE, Matlaf LA, Soroceanu L, Klemm K, Britt WJ, Wang W, Bland KI, Cobbs CS (2010) Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae 1: 8.
41. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62: 3347-3350.
42. Hwang ES, Zhang Z, Cai H, Huang DY, Huong SM, Cha CY, Huang ES (2009) Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. J Virol 83: 12388-12398.
43. Shen Y, Zhu H, Shenk T (1997) Human cytomegalovirus IE1 and IE2 proteins are mutagenic and mediate "hit-and-run" oncogenic transformation in cooperation with the adenovirus E1A proteins. Proc Natl Acad Sci USA 94: 3341-3345.
44. E X, Pickering MT, Debatis M, Castillo J, Lagadinos A, Wang S, Lu S, Kowalik TF (2011) An E2F1-mediated DNA damage response contributes to the replication of human cytomegalovirus. PLoS Pathog 7: e1001342.
45. Castillo JP, Frame FM, Rogoff HA, Pickering MT, Yurochko AD, Kowalik TF (2005) Human cytomegalovirus IE1-72 activates ataxia telangiectasia mutated kinase and a p53/p21-mediated growth arrest response. J Virol 79: 11467-11475.
46. Hume AJ, Kalejta RF (2009) Regulation of the retinoblastoma proteins by the human herpesviruses. Cell Div 4: 1.
47. Soroceanu L, Cobbs CS (2011) Is HCMV a tumor promoter? Virus Res 157: 193-203.
48. Cinatl J Jr, Cinatl J, Vogel JU, Rabenau H, Kornhuber B, Doerr HW (1996) Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells. Intervirology 39: 259-269.
49. Barami K (2010) Oncomodulatory mechanisms of human cytomegalovirus in gliomas. J Clin Neurosci 17: 819-823.
50. Söderberg-Nauclér C, Johnsen JI (2012) Cytomegalovirus infection in brain tumors: a potential new target for therapy? Oncoimmunology 1: 739-740.
51. Maussang D, Verzijl D, van Walsum M, Leurs R, Holl J, Pleskoff O, Michel D, van Dongen GA, Smit MJ (2006) Human cytomegalovirusencoded chemokine receptor US28 promotes tumorigenesis. Proc Natl Acad Sci USA 103: 13068-13073.
52. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman AD, McLendon RE, Sampson JH (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 10: 10-18.
53. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R (2008) Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 116: 79-86.
54. Shen CY, Ho MS, Chang SF, Yen MS, Ng HT, Huang E-S, Wu CW (1993) High rate of concurrent genital infections with human cytomegalovirus and human papillomaviruses in cervical cancer patients. J Infect Dis 168: 449-452.
55. Rahbar A, Stragliotto G, Orrego A, Peredo I, Taher C, Willems J, Söderberg-Naucler C (2012) Low levels of human cytomegalovirus infection in glioblastoma multiforme associates with patient survival-a case-control study. Herpesviridae 3: 3.
56. Dumortier J, Streblow DN, Moses AV, Jacobs JM, Kreklywich CN, Camp D, Smith RD, Orloff SL, Nelson JA (2008) Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing. J Virol 82: 6524-6535.
57. Fortunato EA, Spector DH (2003) Viral induction of site-specific chromosome damage. Rev Med Virol 13: 21-37.
58. Adler SP (2005) Congenital cytomegalovirus screening. Pediatr Infect Dis J 24: 1105-1106.
59. Adler SP (2011) Screening for cytomegalovirus during pregnancy. Infect Dis Obstet Gynecol 2011: 1-9.
60. Nigro G, Adler SP (2011) Cytomegalovirus infections during pregnancy. Curr Opin Obstet Gynecol 23: 123-128.
61. Marshall BC, Adler SP (2009) The frequency of pregnancy and exposure to cytomegalovirus infections among women with a young child in day care. Am J Obstet Gynecol 200: 163. e1-163. e5.
62. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326: 663-667.
63. Ross SA, Boppana SB (2005) Congenital cytomegalovirus infection: outcome and diagnosis. Semin Pediatr Infect Dis 16: 44-49.
64. Vancikova Z, Dvorak P (2001) Cytomegalovirus infection in immunocompetent and immunocompromised individuals-a review. Curr Drug Targets Immune Endocr Metabol Disord 1: 179-187.
65. Mussi-Pinhata MM, Yamamoto AY, Moura Brito RM, de Lima Isaac M, de Carvalho Oliveira PF, Boppana S, Britt WJ (2009) Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population. Clin Infect Dis 49: 522-528.
66. Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA (1992) Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J 11: 93-99.
67. Nassetta L, Kimberlin D, Whitley R (2009) Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. J Antimicrob Chemother 63: 862-867.
68. Bale JF Jr, Blackman JA, Sato Y (1990) Outcome in children with symptomatic congenital cytomegalovirus infection. J Child Neurol 5: 131-136.
69. Williamson WD, Percy AK, Yow MD, Gerson P, Catlin FI, Koppelman ML, Thurber S (1990) Asymptomatic congenital cytomegalovirus infection. Audiologic, neuroradiologic, and neurodevelopmental abnormalities during the first year. Am J Dis Child 144: 1365-1368.
70. Saigal S, Lunyk O, Larke RP, Chernesky MA (1982) The outcome in children with congenital cytomegalovirus infection. A longitudinal follow-up study. Am J Dis Child 136: 896-901.
71. Stagno S, Pass RF, Cloud G, Britt WJ, Henderson RE, Walton PD, Veren DA, Page F, Alford CA (1986) Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 256: 1904-1908.
72. Boppana SB, Fowler KB, Britt WJ, Stagno S, Pass RF (1999) Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics 104: 55-60.
73. Stagno S, Pass RF, Dworsky ME, Alford CA Jr (1982) Maternal cytomegalovirus infection and perinatal transmission. Clin Obstet Gynecol 25: 563-576.
74. Cannon MJ, Hyde TB, Schmid DS (2011) Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection. Rev Med Virol 21: 240-255.
75. Reynolds DW, Stagno S, Hosty TS, Tiller M, Alford CA Jr (1973) Maternal cytomegalovirus excretion and perinatal infection. N Engl J Med 289: 1-5.
76. Dworsky M, Yow M, Stagno S, Pass RF, Alford C (1983) Cytomegalovirus infection of breast milk and transmission in infancy. Pediatrics 72: 295-299.
77. Jim WT, Shu CH, Chiu NC, Kao HA, Hung HY, Chang JH, Peng CC, Hsieh WS, Liu KC, Huang FY (2004) Transmission of cytomegalovirus from mothers to preterm infants by breast milk. Pediatr Infect Dis J 23: 848-851.
78. Vochem M, Hamprecht K, Jahn G, Speer CP (1998) Transmission of cytomegalovirus to preterm infants through breast milk. Pediatr Infect Dis J 17: 53-58.
79. Chiba S, Hori S, Kawamura N, Nakao T (1975) Primary cytomegalovirus infection and liver involvement in early infancy. Tohoku J Exp Med 117: 143-151.
80. Stagno S, Brasfield DM, Brown MB, Cassell GH, Pifer LL, Whitley RJ, Tiller RE (1981) Infant pneumonitis associated with cytomegalovirus, Chlamydia, Pneumocystis, and Ureaplasma: a prospective study. Pediatrics 68: 322-329.
81. Kumar ML, Nankervis GA, Cooper AR, Gold E (1984) Postnatally acquired cytomegalovirus infections in infants of CMV-excreting mothers. J Pediatr 104: 669-673.
82. Ballard RA, Drew WL, Hufnagle KG, Riedel PA (1979) Acquired cytomegalovirus infection in preterm infants. Am J Dis Child 133: 482-485.
83. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG (1981) Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 98: 281-287.
84. Hamprecht K, Maschmann J, Vochem M, Dietz K, Speer CP, Jahn G (2001) Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet 357: 513-518.
85. Eisenfeld L, Silver H, McLaughlin J, Klevjer-Anderson P, Mayo D, Anderson J, Herson V, Krause P, Savidakis J, Lazar A, Rosenkrantz T, Pisciotto P (1992) Prevention of transfusionassociated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion 32: 205-209.
86. Gilbert GL, Hayes K, Hudson IL, James J (1989) Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet 1: 1228-1231.
87. Chou SW (1986) Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 314: 1418-1423.
88. Drew WL, Sweet ES, Miner RC, Mocarski ES (1984) Multiple infections by cytomegalovirus in patients with acquired immunodefi-ciency syndrome: documentation by southern blot hybridization. J Infect Dis 150: 952-953.
89. Grundy JE, Lui SF, Super M, Berry NJ, Sweny P, Fernando ON, Moorhead J, Griffiths PD (1988) Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus. Lancet 2: 132-135.
90. Snydman DR, Werner BG, Heinze-Lacey B, Berardi VP, Tilney NL, Kirkman RL, Milford EL, Cho SI, Bush HL Jr, Levey AS, Strom TB, Carpenter CB, Levey RH, Harmon WE, Zimmerman CE II, Shapiro ME, Steinman T, LoGerfo F, Idelson B, Schröter GPJ, Levin MJ, McIver J, Leszczynski J, Grady GF (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317: 1049-1054.
91. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1995) Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333: 1038-1044.
92. Plotkin SA, Smiley ML, Friedman HM, Starr SE, Fleisher GR, Wlodaver C, Dafoe DC, Friedman AD, Grossman RA, Barker CF (1984) Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1: 528-530.
93. Erice A, Gil-Roda C, Perez JL, Balfour HH Jr, Sannerud KJ, Hanson MN, Boivin G, Chou S (1997) Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 175: 1087-1092.
94. Legendre CM, Norman DJ, Keating MR, Maclaine GD, Grant DM (2000) Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. Transplantation 70: 1463-1468.
95. Mauskopf JA, Richter A, Annemans L, Maclaine G (2000) Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice. Pharmacoeconomics 18: 239-251.
96. Boeckh M, Geballe AP (2011) Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 121: 1673-1680.
97. Kowalsky S, Arnon R, Posada R (2013) Prevention of cytomegalovirus following solid organ transplantation: a literature review. Pediatr Transplant 17: 499-509.
98. Eid AJ, Razonable RR (2010) New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 70: 965-981.
99. Ljungman P, Hakki M, Boeckh M (2011) Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am 25: 151-169.
100. Boeckh M, Bowden R (1995) Cytomegalovirus infection in marrow transplantation. Cancer Treat Res 76: 97-136.
101. Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L (2003) Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101: 407-414.
102. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J (2003) Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9: 543-558.
103. Ljungman P (1996) Cytomegalovirus infections in transplant patients. Scand J Infect Dis Suppl 100: 59-63.
104. Hebart H, Kanz L, Jahn G, Einsele H (1998) Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects. Drugs 55: 59-72.
105. Prentice HG, Kho P (1997) Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant. Bone Marrow Transplant 19: 135-142.
106. Akalin E, Sehgal V, Ames S, Hossain S, Daly L, Barbara M, Bromberg JS (2003) Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 3: 731-735.
107. Limaye AP, Bakthavatsalam R, Kim HW, Kuhr CS, Halldorson JB, Healey PJ, Boeckh M (2004) Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 78: 1390-1396.
108. Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV (2001) Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 184: 1461-1464.
109. Barry PA, Pratt-Lowe E, Peterlin BM, Luciw PA (1990) Cytomegalovirus activates transcription directed by the long terminal repeat of human immunodeficiency virus type 1. J Virol 64: 2932-2940.
110. McKeating JA, Griffiths PD, Weiss RA (1990) HIV susceptibility conferred to human fibroblasts by cytomegalovirus-induced Fc receptor. Nature 343: 659-661.
111. Griffiths PD (2006) CMV as a cofactor enhancing progression of AIDS. J Clin Virol 35: 489-492.
112. Ostrowski MA, Krakauer DC, Li Y, Justement SJ, Learn G, Ehler LA, Stanley SK, Nowak M, Fauci AS (1998) Effect of immune activation on the dynamics of human immunodeficiency virus replication and on the distribution of viral quasispecies. J Virol 72: 7772-7784.
113. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE (1992) Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 166: 1223-1227.
114. Cheung TW, Teich SA (1999) Cytomegalovirus infection in patients with HIV infection. Mt Sinai J Med 66: 113-124.
115. Deayton J, Mocroft A, Wilson P, Emery VC, Johnson MA, Griffiths PD (1999) Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. AIDS 13: 1203-1206.
116. O'Sullivan CE, Drew WL, McMullen DJ, Miner R, Lee JY, Kaslow RA, Lazar JG, Saag MS (1999) Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. J Infect Dis 180: 847-849.
117. Jacobson MA, Schrier R, McCune JM, Torriani FJ, Holland GN, O'Donnell JJ, Freeman WR, Bredt BM (2001) Cytomegalovirus (CMV)-specific CD4+ T lymphocyte immune function in long-term survivors of AIDS-related CMV end-organ disease who are receiving potent antiretroviral therapy. J Infect Dis 183: 1399-1404.
118. Spector SA, Hsia K, Crager M, Pilcher M, Cabral S, Stempien MJ (1999) Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 73: 7027-7030.
119. Deayton JR, Sabin CA, Johnson MA, Emery VC, Wilson P, Griffiths PD (2004) Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 363: 2116-2121.
120. Dock JN, Effros RB (2011) Role of CD8 T cell replicative senescence in human aging and in HIV-mediated immunosenescence. Aging Dis 2: 382-397.